logo
logo

Leucid Bio Raises £11.5M In Series A Financing To Develop Next Generation Of Innovative Chimeric Antigen Receptor T Cell (Car-T) Therapies

Oct 21, 2021•over 3 years ago

Amount Raised

£11.5 Million

Round Type

series a

London

Description

Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces that it has successfully raised £11.5 million in a Series A financing round. The investment was led by Epidarex and new investor Vulpes Investment Management, with participation from new investors 2Invest and Future Fund of the British Business Bank, and existing investor Sofinnova Partners. Proceeds from the financing will be used to initiate a Phase 1 trial of its lead candidate, LEU-011, for the treatment of platinum resistant ovarian cancer.

Company Information

Company

Leucid Bio

Location

London, Ontario, Canada

About

Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumours. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part of Leucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical and manufacturing expertise of Dr Maher and his academic team of immuno-oncology experts. Leucid is headquartered in London, UK, with operations based at Guy's Hospital with its own GMP manufacturing and clinical lab facilities, enabling it to maintain its patient-centric focus on developing better cell therapies for the benefit of individuals with hard-to-treat solid tumours.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech